908 Devices Inc. filings document an operating company that sells common stock under MASS on the Nasdaq Global Market and reports on handheld chemical analysis tools used in health, safety and defense technology markets. Form 8-K reports furnish operating and financial results, revenue outlook materials, material-event disclosures, material agreements, capital-structure matters and related exhibits.
Proxy materials cover annual meeting voting matters, including director elections, auditor ratification, executive compensation votes and the frequency of future advisory compensation votes. The filing record also includes governance disclosures tied to board composition, annual meeting procedures, shareholder voting mechanics and emerging growth company status.
908 Devices Inc. completed the acquisition of Swiss-based NIRLAB, a near‑infrared spectroscopy company, for a preliminary $15 million, split between $13 million in cash and 293,368 shares of common stock, plus up to $8 million in stock earn‑outs tied to revenue milestones through December 31, 2027.
Q1 2026 revenue was $13.4 million, up 14% year over year, with growth in both mass spectrometry and FTIR products. GAAP gross margin improved to 51%, and adjusted gross margin to 57%, while adjusted EBITDA loss narrowed to $2.5 million. The company reported a continuing-operations net loss of about $12.0 million, supported by $111.7 million of cash, cash equivalents and marketable securities and no debt as of March 31, 2026.
The installed base grew 23% to 3,903 devices, with recurring revenue at 30% of total. Management raised full‑year 2026 revenue guidance to a range of $67.0–$70.0 million, representing 19%–25% growth versus 2025.
908 Devices Inc. SVP John Kenneweg reported a routine equity compensation event involving vested performance stock units (PSUs) and a related tax sale. On May 1, 2026, 26,042 PSUs vested and were converted into 26,042 shares of Common Stock. To cover tax withholding obligations from this vesting, 7,787 shares of Common Stock were sold in an open-market “sell to cover” transaction at $6.83 per share, a sale mandated by the company’s election and described as non-discretionary for the insider. Following these transactions, Kenneweg directly holds 76,039 shares of Common Stock, and all of the reported PSUs have been fully settled.
Kenneweg John reported acquisition or exercise transactions in this Form 4 filing.
908 Devices Inc. reported that SVP of Sales & Product Marketing John Kenneweg received a grant of 26,042 Performance Stock Units. Each unit represents a contingent right to receive one share of Common Stock with a par value of $0.001 when it vests.
The compensation committee certified achievement of the required performance metrics and goals on April 28, 2026, and the PSUs are scheduled to vest on May 1, 2026 in accordance with their terms. The PSUs have no expiration date, and this filing reflects a compensation-related equity award rather than an open-market trade.
908 Devices Inc. is asking stockholders to vote at its 2026 Annual Meeting, held virtually on June 11, 2026 at 10:00 a.m. Eastern Time. The meeting will be online only via a webcast platform.
Stockholders will vote on electing three Class III directors to terms ending in 2029, ratifying PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, and approving on an advisory basis the compensation of named executive officers. They will also give an advisory recommendation on how often future say‑on‑pay votes should occur, with the board favoring a one‑year frequency.
Holders of 37,446,534 shares of common stock outstanding as of April 16, 2026 are entitled to vote. The board recommends voting for all director nominees, for auditor ratification, for the say‑on‑pay resolution, and for annual say‑on‑pay frequency.
908 Devices Inc. reported equity compensation grants to Chief Business & Strategy Officer Otitoju Kolawole A. on April 21, 2026. He received 110,193 restricted stock units, each representing one share of common stock, vesting in three substantially equal annual installments on the anniversaries following May 1, 2026, subject to continued service.
He was also granted a stock option for 146,789 shares of common stock at an exercise price of $7.26 per share, expiring on April 20, 2036. One-third of these option shares vest on May 1, 2027, with the remaining two-thirds vesting in substantially equal monthly installments over the following 24 months, contingent on continued service. These are compensation awards rather than open-market purchases or sales.
908 Devices Inc. filed an initial ownership report on Form 3 for Otitoju Kolawole A., who serves as Chief Business & Strategy Officer. This filing establishes his status as an officer and discloses that there are currently no reportable transactions or holdings listed in this statement.
908 Devices Inc. senior vice president Kevin J. McCallion exercised stock options for 2,693 shares of common stock at $1.05 per share and sold the same 2,693 shares at a weighted average price of $7.01 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was pre‑scheduled. Following the transactions, he directly holds 44,925 shares of common stock, and the underlying option grant is now fully exercised.
908 Devices Inc. senior vice president Kevin J. McCallion exercised employee stock options and immediately sold the resulting shares in planned trades. He exercised options for 24,000 shares of common stock at $1.05 per share, then sold 24,000 shares in open-market transactions at weighted-average prices around $7.04 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was scheduled in advance. After these transactions, McCallion directly holds 44,925 shares of 908 Devices common stock.
908 Devices Inc. director Christopher D. Brown reported open-market sales of 40,000 shares of Common Stock. The transactions occurred over three days at prices around $7 per share, under a Rule 10b5-1 trading plan adopted on November 24, 2025.
Brown sold 15,030 shares at a weighted average price of $7.05 on April 8, 7,392 shares at $7.04 on April 9, and 17,578 shares at $7.07 on April 10. After these sales, he continues to hold 945,559 shares directly, indicating he retains a substantial equity position in the company.